Symposia: Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Antibody Therapy, Acute Myeloid Malignancies, AML, adult, Non-Biological therapies, Clinical Research, Chemotherapy, Combination therapy, drug development, pediatric, Diseases, Therapies, Immunotherapy, Adverse Events, Monoclonal Antibody Therapy, Myeloid Malignancies, Radiation Therapy, Study Population, Human, Minimal Residual Disease
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Antibody Therapy, Acute Myeloid Malignancies, AML, adult, Non-Biological therapies, Clinical Research, Chemotherapy, Combination therapy, drug development, pediatric, Diseases, Therapies, Immunotherapy, Adverse Events, Monoclonal Antibody Therapy, Myeloid Malignancies, Radiation Therapy, Study Population, Human, Minimal Residual Disease
Saturday, December 10, 2022: 9:30 AM-11:00 AM
220-222
(Ernest N. Morial Convention Center)
Moderators:
Jonathan M Gerber, MD, Umass Medical School
and
Catherine Lai, MD, MPH, University of Pennsylvania
Disclosures:
Lai: Jazz Pharma: Speakers Bureau; Astellas: Speakers Bureau; Jazz Pharma: Consultancy; Jazz Pharma: Research Funding; Genentech: Consultancy; Novartis: Consultancy; Abbvie: Consultancy; Taiho: Consultancy; Pfizer: Consultancy; PDS Biotechnology: Consultancy; Macrogenics: Consultancy; Astellas: Consultancy; Daiichi Sankyo: Consultancy.
This session will focus on investigational therapies for relapsed/refractory AML, including novel agents and novel therapeutic combinations.
9:30 AM
9:45 AM
10:00 AM
10:15 AM
10:30 AM
10:45 AM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH